

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)



(10) International Publication Number
WO 2023/178093 A1

(51) International Patent Classification:
C07C 57/50 (2006.01) C07C 57/26 (2006.01)
C07C 57/03 (2006.01)

(21) International Application Number:
PCT/US2023/064325

(22) International Filing Date:
14 March 2023 (14.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/320,159 15 March 2022 (15.03.2022) US

(71) Applicant: **IO THERAPEUTICS, INC.** [US/US]; 9450
Pinecroft Dr., Unit 9497, Spring, Texas 77387 (US).

(72) Inventors: **VULIGONDA, Vidyasagar**; 9450 Pinecroft
Dr., Unit 9497, Spring, Texas 77387 (US). **SANDERS,
Martin E.**; 9450 Pinecroft Dr., Unit 9497, Spring, Texas
77387 (US). **KUANG, Shanming**; 2106 Pheasant Hollow
Drive, Plainsboro, New Jersey 08536 (US). **SHAH, Harsh
Shailesh**; 6 Cedar Brook Dr, Cranbury, New Jersey 08512
(US).

(74) Agent: **GLASKY BERGMAN, Michelle**; 1 Park Plaza,
12th Floor, Irvine, California 92614 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: RXR AGONIST SALT FORMS, POLYMORPHS THEREOF, AND USES THEREOF




FIG. 1

(57) **Abstract:** Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5, 5, 8, 8-tetramethyl-5, 6, 7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses. This disclosure also generally describes (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5, 5, 8, 8-tetramethyl-5, 6,7,8- tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid (Compound 1) as a tris(hydroxymethyl)aminomethane (Tris) salt form and polymorphic forms thereof. Compositions comprising such forms, including pharmaceutical compositions generally and formulations for particular routes of administration, are also described. Therapeutic or prophylactic uses of such forms and compositions as a monotherapy or in combination with one or more other active pharmaceutical agents, including thyroid hormone or neurotrophic factors, are also described.

[Continued on next page]

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*